Nyxoah SA (EBR:NYXH)
3.195
-0.040 (-1.24%)
At close: Mar 6, 2026
Nyxoah Revenue
Nyxoah had revenue of 1.97M EUR in the quarter ending September 30, 2025, with 55.77% growth. This brings the company's revenue in the last twelve months to 5.64M, up 10.96% year-over-year. In the year 2024, Nyxoah had annual revenue of 4.52M with 3.98% growth.
Revenue (ttm)
5.64M
Revenue Growth
+10.96%
P/S Ratio
22.85
Revenue / Employee
30.65K
Employees
184
Market Cap
128.86M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| argenx SE | 3.62B |
| Financière de Tubize | 13.26K |
| Fagron NV | 952.17M |
| Ion Beam Applications | 585.76M |
| Onward Medical | 2.72M |
| Hyloris Pharmaceuticals | 8.46M |
| Sequana Medical NV | 105.50K |
Nyxoah News
- 19 days ago - Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East - GlobeNewsWire
- 6 weeks ago - Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth - GlobeNewsWire
- 2 months ago - Publication relating to transparency notification - GlobeNewsWire
- 2 months ago - Nyxoah Announces Issuance of First Tranche of Convertible Bonds - GlobeNewsWire
- 2 months ago - Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands - GlobeNewsWire
- 3 months ago - Publication relating to transparency notifications - GlobeNewsWire
- 3 months ago - Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - GlobeNewsWire